• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Premarket Approval (PMA)

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | Registration & Listing | Adverse Events | Recalls | PMA | Classification | Standards | Inspections
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 


New Search Back to Search Results
Note: this medical device has supplements. The device description may have changed. Be sure to look at the supplements to get an up-to-date view of this device.
 
Trade NamePROGENSA PCA3 ASSAY
Classification Nameprostrate cancer genes nucleic acid amplification test system
ApplicantGEN-PROBE INCORPORATED
PMA NumberP100033
Date Received08/10/2010
Decision Date02/13/2012
Product Code
OYM[ Registered Establishments with OYM ]
Docket Number 12M-0173
Notice Date 03/06/2012
Advisory Committee Immunology
Clinical Trials NCT01024959
Expedited Review Granted? No
Combination Product No
Information About: Labeling, Approval Order, Summary of Safety and Effectiveness
Approval Order Statement 
Approval for the progensa pca3 assay. This device is indicated for: progensa pca3 assay is an in vitro nucleic acid amplification test. The assay measures the concentration of prostate cancer gene 3 (pca3) and prostate-specific antigen (psa) rna (rna) molecules and calculates the ratio of pca3 rna molecules to psa rna molecules (pca3 score) in post digital rectal exam (dre) first catch male urine specimens. The progensa pca3 assay is indicated for use in conjunction with other patient information to aid in the decision for repeat biopsy in men 50 years of age or older who have had one or more previous negative prostate biopsies and for whom a repeat biopsy would be recommended by a urologist based on current standard of care, before consideration of progensa pca3 assay results. A pca3 score <25 is associated with a decreased likelihood of a positive biopsy. Prostatic biopsy is required for diagnosis of cancer.
Approval Order Approval Order
Supplements: S001 
-
-